CRL is expected to report earnings to rise 32.52% to $2.73 per share on August 12
Q2'26
Est.
$2.73
Q1'26
Beat
by $0.12
Q4'25
Beat
by $0.04
Q3'25
Beat
by $0.09
Q2'25
Beat
by $0.62
The last earnings report on May 07 showed earnings per share of $2.06, beating the estimate of $1.94. With 100.86K shares outstanding, the current market capitalization sits at 8.75B.
A.I. Advisor
published General Information
General Information
a provider of laboratory testing and research services on a contract basis
A.I.dvisor indicates that over the last year, CRL has been closely correlated with IQV. These tickers have moved in lockstep 75% of the time. This A.I.-generated data suggests there is a high statistical probability that if CRL jumps, then IQV could also see price increases.
CRL's RSI Oscillator ascends from oversold territory
The RSI Indicator for CRL moved out of oversold territory on May 19, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 38 similar instances when the indicator left oversold territory. In of the 38 cases the stock moved higher. This puts the odds of a move higher at .
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator is in the oversold zone. Keep an eye out for a move up in the foreseeable future.
The Momentum Indicator moved above the 0 level on June 22, 2026. You may want to consider a long position or call options on CRL as a result. In of 85 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .
CRL moved above its 50-day moving average on May 28, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for CRL crossed bullishly above the 50-day moving average on June 04, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In of 17 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where CRL advanced for three days, in of 288 cases, the price rose further within the following month. The odds of a continued upward trend are .
The Aroon Indicator entered an Uptrend today. In of 220 cases where CRL Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .
Bearish Trend Analysis
The Moving Average Convergence Divergence Histogram (MACD) for CRL turned negative on June 22, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 50 similar instances when the indicator turned negative. In of the 50 cases the stock turned lower in the days that followed. This puts the odds of success at .
Following a 3-day decline, the stock is projected to fall further. Considering past instances where CRL declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
CRL broke above its upper Bollinger Band on May 28, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. CRL’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.974) is normal, around the industry mean (12.431). CRL has a moderately high P/E Ratio (577.050) as compared to the industry average of (145.825). CRL's Projected Growth (PEG Ratio) (0.122) is slightly lower than the industry average of (1.482). CRL has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.008). P/S Ratio (2.215) is also within normal values, averaging (7.245).
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CRL’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Charles River Laboratories International (CRL) stock Forecast, Price Targets and Analysts Predictions - Tickeron.com
